Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02JBI
|
|||
| Former ID |
DIB004222
|
|||
| Drug Name |
SAL-200
|
|||
| Indication | Bacteremia [ICD-11: 1A73; ICD-10: A54.4, A54.8] | Phase 2 | [1] | |
| Staphylococcus infection [ICD-11: 1B5Y] | Phase 1 | [2] | ||
| Company |
INtRON Biotechnology Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03089697) Phase IIa Clinical Study of N-Rephasin SAL200. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01855048) A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin SAL200 in Healthy Male Volunteers. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.